Examkin

All practice questions

4736 questions

All types4,736Multiple choice2,413Multiple select567Numeric127Matching858Ordering771
Question 4061Question →

A 62-year-old man presents to the clinic to discuss pancreatic cancer screening. He has no current symptoms of abdominal pain, jaundice, or weight loss. Vital signs are within normal limits, and physical examination is unremarkable. His father and paternal uncle both died of pancreatic adenocarcinoma, prompting his enrollment in a high-risk familial surveillance registry. Epidemiological data indicates that the prevalence of early-stage pancreatic adenocarcinoma in this specific surveillance cohort is 10%10\%.

As part of a new clinical protocol, the patient's blood is tested using a novel multi-target serum biomarker panel. The assay has a validated sensitivity of 90%90\% and a specificity of 90%90\% for detecting early-stage disease.

The patient's biomarker panel returns a positive result.

Based on the provided test characteristics and cohort prevalence, what is the post-test probability (in percent) that this patient actually has early-stage pancreatic adenocarcinoma?

Show answer & explanation

Answer: 50

Answer

50
The question asks for the post-test probability of disease following a positive test result, which is the positive predictive value (PPV) of the assay. PPV depends on the test's sensitivity and specificity, as well as the disease prevalence in the tested population.

Using a hypothetical cohort of 10001000 patients:
- Number of patients with disease: 1000×0.10=1001000 \times 0.10 = 100
- Number of patients without disease: 1000×0.90=9001000 \times 0.90 = 900

Next, calculate the number of positive test results in each group:
- True positives (TP) = 100×0.90 (sensitivity)=90100 \times 0.90 \text{ (sensitivity)} = 90
- False positives (FP) = 900×(1−0.90 specificity)=90900 \times (1 - 0.90 \text{ specificity}) = 90

The total number of positive test results is 90 (TP)+90 (FP)=18090 \text{ (TP)} + 90 \text{ (FP)} = 180.

PPV = TPTP+FP=90180=0.50\frac{\text{TP}}{\text{TP} + \text{FP}} = \frac{90}{180} = 0.50 (or 50%50\%).

Therefore, the probability that the patient has early-stage pancreatic adenocarcinoma is 50%50\%.

Step-by-Step Solution

1
Determine the disease prevalence in the cohort.
The prevalence is 10%, meaning in a population of 1000, 100 have the disease and 900 do not.
Prevalence establishes the pre-test probability necessary for calculating predictive values.
2
Calculate the true positive (TP) and false positive (FP) counts.
TP = 100 × 0.90 = 90. FP = 900 × 0.10 = 90.
Using absolute numbers derived from sensitivity and specificity clarifies the ratio of true to false positive results.
3
Calculate the Positive Predictive Value (PPV).
PPV = TP / (TP + FP) = 90 / (90 + 90) = 0.50, or 50%.
The PPV directly represents the post-test probability of disease following a positive test result.

Key Concept

Positive predictive value (PPV) and its dependence on disease prevalence.
Question 4062Question →

An occupational medicine physician working for a national labor union is evaluating the long-term health impacts of a specific synthetic resin used at a single large aerospace manufacturing plant. The resin was utilized continuously from 2000 to 2015 before being phased out. The physician aims to determine if there is an association between handling this resin and the subsequent development of interstitial lung disease.

Using the plant's archived human resources logs, the physician categorizes 800 former employees based on whether their daily job duties involved direct contact with the resin. The physician then cross-references these two groups with state health registries from 2000 to 2026 to calculate and compare the incidence of interstitial lung disease between the exposed and unexposed workers.

Which of the following best describes the design of this investigation?

Show answer & explanation

Answer: Retrospective cohort study

Answer

Retrospective cohort study
The correct answer is a retrospective cohort study. In this epidemiological design, the investigator establishes the study groups based on historical exposure status (in this scenario, handling the synthetic resin versus not handling it) using archived records. The investigator then evaluates the subsequent incidence of the outcome (interstitial lung disease) up to the present day. Because the subjects are initially grouped by their exposure, it is a cohort study. Because both the exposure and the disease outcome have already occurred before the investigator begins the study, it is designated as retrospective.

Step-by-Step Solution

1
Identify how the study population was initially grouped.
The subjects were categorized based on their exposure status to the synthetic resin (exposed versus unexposed) using historical HR logs.
Grouping subjects by exposure status rather than disease status is the defining characteristic of a cohort study.
2
Determine the temporal relationship between the study initiation, the exposure, and the outcome.
The investigator is conducting the study in 2026. Both the exposure (2000-2015) and the development of the outcome have already occurred in the past.
Because the investigator looks backward in time to establish the cohort based on past exposure and traces the outcomes up to the present day, the cohort study is retrospective.

Key Concept

A retrospective cohort study uses historical data to group subjects by past exposure status and then tracks the subsequent incidence of a disease up to the present.
Question 4063Question →

Investigators are conducting a randomized, two-period crossover trial evaluating a novel targeted biologic therapy for chronic spontaneous urticaria. The initial power analysis determined that a total of 40 patients (20 receiving the biologic followed by placebo, and 20 receiving placebo followed by the biologic) would provide 90% power to detect a clinically significant reduction in symptom severity scores at a two-tailed α\alpha of 0.05.

Following the initiation of the trial, an interim pharmacokinetic analysis reveals that the biologic has an unexpectedly long half-life. This results in a profound carryover effect that extends well beyond the planned 6-week washout period. To preserve the integrity of the data, the trial steering committee decides to discard all Period 2 data entirely. The study will now be analyzed as a standard two-arm parallel randomized controlled trial using exclusively the Period 1 data (20 patients in the biologic arm and 20 patients in the placebo arm).

Assuming the true effect size of the biologic remains unchanged, which of the following is the most likely statistical consequence of this protocol modification?

Show answer & explanation

Answer: The statistical power of the study will decrease primarily because the analysis must now incorporate inter-subject rather than intra-subject variance

Answer

The statistical power of the study will decrease primarily because the analysis must now incorporate inter-subject rather than intra-subject variance.
Statistical power is the probability of correctly rejecting the null hypothesis when a true difference exists (Power = 1−β1 - \beta). Power is heavily dependent on the variance of the data. In a crossover design, each patient acts as their own control. The statistical analysis (such as a paired t-test) evaluates the difference in outcomes within the same person, relying on intra-subject variance. Because an individual's baseline characteristics are perfectly matched with themselves, intra-subject variance is typically very low, yielding high statistical power.

When the trial is converted to a parallel-group design, the biologic group is now compared to a completely different group of people (the placebo group). The analysis (such as an independent samples t-test) must now incorporate inter-subject variance, which accounts for the natural physiological differences between different human beings. This variance is substantially larger. The combination of utilizing a larger variance term and halving the total number of outcome measurements drastically reduces the statistical power of the study and increases the risk of a Type II error.

Step-by-Step Solution

1
Identify the core statistical advantage of the original crossover design.
In a crossover trial, each subject receives both treatments, serving as their own control. This allows the statistical test to use intra-subject variance.
Intra-subject variance is almost always smaller than inter-subject variance, providing higher statistical power for a given number of participants.
2
Determine the impact of the protocol modification.
Discarding Period 2 converts the study into a parallel-group trial. The effective sample size of observations is halved, and the groups are now composed of different individuals.
The carryover effect contaminated Period 2, making the data unusable.
3
Analyze how the shift to a parallel design affects variance and statistical power.
Because different individuals are now being compared, the analysis must use inter-subject variance. The combination of a smaller sample size (fewer total measurements) and a larger variance term significantly decreases the ability to detect a true difference.
Statistical power is inversely proportional to variance and directly proportional to sample size.
4
Relate power to Type II error.
A decrease in statistical power corresponds directly to an increase in the probability of a Type II error (β\beta).
Power is mathematically defined as 1−β1 - \beta.

Key Concept

Crossover study designs yield higher statistical power than parallel designs primarily because they rely on intra-subject variance (comparing a patient to themselves) rather than inter-subject variance. Converting a crossover trial to a parallel trial increases variance and decreases power.
Question 4064Question →

During a comprehensive health maintenance examination, a physician evaluates a 55-year-old female patient who reports a persistent morning cough. History reveals she has consumed one pack of cigarettes daily for three decades. The clinician decides to implement the US Preventive Services Task Force (USPSTF) recommended behavioral framework for tobacco cessation.

Arrange the following physician actions in the correct sequential order according to this evidence-based framework.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence for the tobacco cessation behavioral framework is: Ask about tobacco use, Advise the patient to quit, Assess willingness to quit, Assist in the quit attempt, and Arrange follow-up.
The US Preventive Services Task Force (USPSTF) recommends the '5 A's' model for treating tobacco use and dependence. The model follows a strict logical sequence to maximize efficacy and respect patient autonomy: 1) ASK: Systematically identify all tobacco users at every clinical visit. 2) ADVISE: Strongly urge all tobacco users to quit using personalized messaging. 3) ASSESS: Determine willingness to make a quit attempt at the current time. 4) ASSIST: Aid the patient in quitting through medications and practical counseling. 5) ARRANGE: Ensure follow-up contact to prevent relapse.

Step-by-Step Solution

1
Identify the recommended behavioral counseling framework for tobacco cessation.
The USPSTF recommends the '5 A's' framework: Ask, Advise, Assess, Assist, Arrange.
Recognizing the standardized protocol is essential for answering questions about preventive care and lifestyle counseling.
2
Map the specific clinical actions provided in the items to the conceptual steps of the framework.
Querying = Ask; Urging to stop = Advise; Inquiring about commitment = Assess; Prescribing therapy = Assist; Scheduling follow-up = Arrange.
Applying theoretical knowledge to practical, patient-centered actions demonstrates competence in health education.

Key Concept

The 5 A's Behavioral Counseling Framework for Tobacco Cessation
Question 4065Question →

An 82-year-old woman is admitted with a severe ischemic stroke and is now deemed medically stable for discharge. She has profound expressive aphasia and cognitive deficits, rendering her unable to participate in complex medical decision-making. The multidisciplinary team determines she requires intensive physical rehabilitation and 24-hour nursing care. Arrange the following steps in the most appropriate chronological order to facilitate a safe, ethical, and effective transition of care.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct chronological sequence is: 1) Document formal capacity assessment, 2) Identify and engage the healthcare surrogate, 3) Select the appropriate facility with the surrogate, 4) Transmit documentation and medication reconciliation, and 5) Coordinate physical transportation.
The safe and ethical disposition of a patient who cannot make their own decisions requires a strict chronological workflow. First, the medical team must establish and document that the patient lacks decision-making capacity. Only then can they legally turn to a healthcare surrogate. Once the surrogate is engaged, shared decision-making is utilized to select an appropriate post-acute care setting. After a specific facility is selected, the hospital must transmit necessary clinical documentation—including a thorough medication reconciliation—to ensure the facility can safely manage the patient and formally accept the transfer. Only after acceptance is secured should physical transportation be coordinated.

Step-by-Step Solution

1
Assess decision-making capacity
The patient is formally documented as lacking the capacity to make disposition decisions.
Capacity must be formally assessed before transferring decision-making rights to another party.
2
Engage healthcare surrogate
A legally authorized decision-maker is identified and informed of the clinical situation.
A surrogate is legally required to make disposition choices for an incapacitated patient.
3
Select care facility
A facility that meets medical needs and surrogate preferences is chosen.
Patient-centered care requires aligning medical rehabilitation needs with the surrogate's goals and choices.
4
Transmit clinical documentation
The receiving facility reviews the clinical case, reviews the medication reconciliation, and accepts the patient.
Proper handoff is critical for continuity of care and is a prerequisite for facility acceptance.
5
Coordinate transportation
The patient is physically transferred to the new care setting.
Transport can only occur safely after the receiving facility has officially accepted the patient.

Key Concept

Ethical and safe disposition planning for patients lacking decision-making capacity requires a stepwise approach: formal capacity assessment, surrogate identification, shared decision-making for facility selection, thorough clinical handoff, and finally, physical transfer.
Estimated Time:1m 30s
Question 4066Question →

A large integrated healthcare delivery system plans to evaluate the effectiveness of a new pharmacist-led telephone counseling program aimed at improving medication adherence in patients with newly diagnosed heart failure. To avoid having physicians unintentionally apply the novel counseling techniques to patients in the control group, the researchers decide to randomize individual primary care clinics, rather than individual patients, to either implement the new program or continue with standard care. Which of the following statements regarding this specific study design are correct?

Select all that apply

Show answer & explanation

Answer: It effectively minimizes the risk of intervention contamination among patients managed by the same healthcare providers.; The required total patient sample size must be adjusted upward to account for intra-cluster correlation.

Answer

The study design minimizes the risk of intervention contamination and requires an upward adjustment of the patient sample size to account for intra-cluster correlation.
Cluster randomized trials randomize intact groups (such as clinics, hospitals, or communities) rather than individuals. This design is highly effective at preventing contamination bias, which would occur if a single provider applied the intervention (e.g., new counseling techniques) to their control patients. However, because patients within the same cluster often share similarities and are treated by the same staff, their outcomes are correlated. This intra-cluster correlation reduces the effective statistical power per patient, meaning investigators must recruit a larger total number of patients compared to an individual-level randomized trial to achieve the same power.

Step-by-Step Solution

1
Identify the study design described in the scenario.
The scenario describes a cluster randomized controlled trial, as groups (clinics) rather than individuals are randomized.
Recognizing the design is essential to evaluating its methodological characteristics and statistical requirements.
2
Evaluate the strengths and methodological requirements of a cluster randomized trial.
Strengths include preventing contamination bias between patients seen by the same providers. Methodological requirements include accounting for the non-independence of observations within a cluster (intra-cluster correlation).
Patients in the same clinic often share similar characteristics and receive care from the same culture/system, violating the assumption of independent observations.
3
Select the statements that correctly align with these methodological principles.
The statements confirming minimized contamination bias and the need for increased sample sizes correctly describe cluster RCTs.
To maintain adequate statistical power when observations are clustered, the design effect must be calculated, which invariably increases the required overall sample size.

Key Concept

Methodological principles and statistical implications of cluster randomized controlled trials.
Question 4067Question →

A 48-year-old man who underwent a deceased-donor kidney transplant 3 years ago is evaluated in the clinic. He reports a 3-day history of a white coating in his mouth. He denies dysphagia, odynophagia, or fever. His current maintenance immunosuppressive regimen includes tacrolimus, mycophenolate mofetil, and prednisone. His allograft function has been stable with a baseline serum creatinine of 1.2 mg/dL1.2\text{ mg/dL}. Today, his temperature is 37.0∘C37.0^\circ\text{C} (98.6∘F98.6^\circ\text{F}). Physical examination reveals adherent white plaques on the buccal mucosa and tongue that can be easily scraped off. Laboratory studies obtained today show a serum creatinine of 1.3 mg/dL1.3\text{ mg/dL} and a tacrolimus trough level of 6.5 ng/mL6.5\text{ ng/mL} (target: 5−8 ng/mL5-8\text{ ng/mL}). The physician diagnoses oropharyngeal candidiasis and plans to prescribe a 14-day course of oral fluconazole. The patient also mentions he forgot to get his annual influenza vaccine and requests it during this visit. Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Preemptively reduce the tacrolimus dose and administer the inactivated influenza vaccine

Answer

The most appropriate next step is to preemptively reduce the tacrolimus dose and administer the inactivated influenza vaccine.
The correct answer requires synthesizing two crucial aspects of outpatient management in a transplant recipient: drug interaction monitoring and preventive care. First, tacrolimus is a calcineurin inhibitor primarily metabolized by the hepatic cytochrome P450 3A4 (CYP3A4) system. Fluconazole is a potent inhibitor of CYP3A4. Initiating fluconazole will rapidly decrease the clearance of tacrolimus, leading to supratherapeutic blood levels that cause acute nephrotoxicity and neurotoxicity. Therefore, standard of care dictates a preemptive reduction of the tacrolimus dose (usually by 25% to 50%) with close monitoring of trough levels a few days later. Second, the patient is requesting his annual influenza vaccine. Solid organ transplant recipients should receive the annual inactivated influenza vaccine. Live-attenuated vaccines (like the intranasal influenza vaccine) are strictly contraindicated due to the risk of unchecked vaccine-strain viral replication.

Step-by-Step Solution

1
Evaluate the planned pharmacotherapy (fluconazole) against the patient's current regimen (tacrolimus).
Identify a major drug-drug interaction: fluconazole is a strong CYP3A4 inhibitor, and tacrolimus is a CYP3A4 substrate.
Recognizing interactions is critical in transplant patients to prevent severe toxicity or graft rejection.
2
Determine the necessary dose adjustment for tacrolimus.
The tacrolimus dose must be preemptively reduced (typically by 25-50%) and trough levels monitored closely.
CYP3A4 inhibition will rapidly increase tacrolimus blood levels, risking nephrotoxicity and neurotoxicity if the dose is left unchanged.
3
Evaluate the patient's request for an influenza vaccine in the context of his immunosuppression.
Determine that the inactivated influenza vaccine is indicated and safe, while the live-attenuated version is contraindicated.
Immunosuppressed patients are at high risk for severe influenza complications but can develop unchecked vaccine-strain infections from live vaccines.

Key Concept

Pharmacokinetic monitoring of CYP3A4 substrates (tacrolimus) when initiating inhibitors (fluconazole), and safe vaccine administration in transplant recipients.
Question 4068Question →

A 58-year-old man with poorly controlled type 2 diabetes mellitus (HbA1c 10.4%) presents for a follow-up visit. He has repeatedly declined insulin therapy in the past, citing a fear of needles and a belief that starting insulin means he has 'failed' at managing his health. The physician decides to utilize the formal, four-process framework of Motivational Interviewing to guide the consultation.

Arrange the following physician statements in the correct chronological sequence reflecting the standard progression of Motivational Interviewing (Engaging, Focusing, Evoking, and Planning).

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence of Motivational Interviewing processes is: Engaging, followed by Focusing, then Evoking, and finally Planning.
Motivational Interviewing follows a sequential four-process framework. It must begin with Engaging to build a collaborative relationship. Next is Focusing, where the physician and patient collaboratively set an agenda. The third process is Evoking, where the physician elicits the patient's own reasons for change (change talk). The final process is Planning, which involves developing a specific, concrete action plan only after readiness to change has been established.

Step-by-Step Solution

1
Identify the statement that establishes the relational foundation (Engaging).
The statement validating the patient's frustration and emphasizing collaboration establishes the necessary working alliance.
Without initial engagement and rapport, the patient is likely to remain defensive and resistant to further discussion.
2
Identify the statement that sets the agenda (Focusing).
The statement asking the patient to choose between discussing diet, oral medications, or injection fears narrows the scope of the visit.
Focusing ensures the consultation is directed toward a specific, mutually agreed-upon target behavior.
3
Identify the statement that draws out the patient's intrinsic motivation (Evoking).
The statement linking blood glucose control to the patient's personal goal of traveling with family elicits 'change talk'.
Evoking relies on the patient articulating their own reasons for change, which is the core mechanism of Motivational Interviewing.
4
Identify the statement that commits to concrete action (Planning).
The statement detailing a three-day practice plan with a demonstration pen represents the final step.
Planning should only occur once sufficient readiness and motivation have been established.

Key Concept

The four foundational, sequential processes of Motivational Interviewing: Engaging, Focusing, Evoking, and Planning.
Question 4069Question →

A 68-year-old woman is evaluated in the emergency department for sudden-onset pleuritic chest pain, dyspnea, and hemoptysis. Her pulse is 115/min, and her respiratory rate is 24/min. Physical examination reveals unilateral right calf swelling and tenderness. Based on clinical scoring, her pretest probability for a pulmonary embolism is categorized as high. A junior resident suggests ordering a high-sensitivity D-dimer assay; if the result is negative, the resident plans to safely exclude the condition and discharge the patient, but if positive, proceed to computed tomography pulmonary angiography (CTPA). Which of the following statistical principles best explains why the resident's proposed diagnostic strategy is flawed?

Show answer & explanation

Answer: The negative predictive value of the initial assay is insufficient to safely exclude the diagnosis in a high-prevalence setting.

Answer

The resident's strategy is flawed because the negative predictive value of the initial assay is insufficient to safely exclude the diagnosis in a high-prevalence setting.
The correct principle is that the negative predictive value (NPV) of a test decreases as the pretest probability of the disease increases. The NPV is mathematically defined as NPV=True NegativesTrue Negatives+False Negatives\text{NPV} = \frac{\text{True Negatives}}{\text{True Negatives} + \text{False Negatives}} In a patient with a high pretest probability of pulmonary embolism (PE), the absolute number of false negatives increases relative to true negatives. Consequently, a negative D-dimer result in this patient does not reliably lower the post-test probability enough to safely exclude PE without further imaging. The standard of care mandates that patients with a high pretest probability bypass the D-dimer test and proceed directly to diagnostic imaging, such as CT pulmonary angiography.

Step-by-Step Solution

1
Identify the patient's pretest probability for the suspected disease.
The patient has a unequivocally high clinical pretest probability for a pulmonary embolism based on her symptoms (hemoptysis, dyspnea, pleuritic pain) and signs (tachycardia, unilateral calf swelling).
Establishing the baseline risk is required to appropriately select and interpret diagnostic tests.
2
Analyze the role of the proposed diagnostic test.
The D-dimer assay is highly sensitive but lacks specificity. It is typically utilized as a rule-out test in low- to intermediate-risk populations.
Tests must be deployed in patient populations where their predictive values yield actionable clinical conclusions.
3
Apply Bayes' theorem to predict test performance in this specific patient.
As the pretest probability of a disease increases, the Negative Predictive Value (NPV) decreases.
NPV is heavily dependent on disease prevalence. In high-risk settings, a negative test is statistically much more likely to be a false negative than a true negative.
4
Evaluate the clinical consequence of the resident's pathway.
A negative D-dimer in this high-risk patient has an unacceptably high false-omission rate. Therefore, the diagnosis cannot be safely excluded, making the test useless.
When a test cannot alter management regardless of the result, it should not be ordered. The patient should proceed directly to definitive imaging (CTPA).

Key Concept

The predictive value of a test depends heavily on pretest probability (disease prevalence). In patients with a high pretest probability, a negative result from a sensitive screening test yields a low Negative Predictive Value (NPV), meaning it cannot safely rule out the disease.
Question 4070Question →

A 54-year-old man is evaluated in the clinic for a new-onset tremor and diffuse headaches that began 5 days ago. He underwent a deceased-donor renal transplantation 8 months ago for end-stage renal disease secondary to hypertensive nephrosclerosis. His maintenance immunosuppressive regimen consists of tacrolimus, mycophenolate mofetil, and low-dose prednisone. Two weeks ago, he was diagnosed with paroxysmal atrial fibrillation; at that time, his primary care physician initiated therapy with diltiazem and apixaban.

On physical examination, blood pressure is 142/88 mmHg and pulse is 78/min and irregularly irregular. A coarse resting tremor is observed in the bilateral upper extremities. The remainder of the examination is unremarkable.

Laboratory studies show:
Serum sodium: 139 mEq/L
Serum potassium: 5.1 mEq/L
Serum chloride: 104 mEq/L
Serum bicarbonate: 22 mEq/L
Blood urea nitrogen: 48 mg/dL
Serum creatinine: 2.6 mg/dL (baseline 1.2 mg/dL)
Serum tacrolimus trough level: 24 ng/mL (target: 5-8 ng/mL)

Renal ultrasound reveals a normal-appearing allograft with no hydronephrosis and normal resistive indices.

Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Discontinue diltiazem and initiate metoprolol

Answer

The correct answer is to discontinue diltiazem and initiate metoprolol.
The correct approach involves recognizing the critical drug-drug interaction between diltiazem and tacrolimus. Tacrolimus is a calcineurin inhibitor metabolized by the cytochrome P450 3A4 (CYP3A4) system. Diltiazem is a non-dihydropyridine calcium channel blocker and a potent inhibitor of CYP3A4. Initiation of diltiazem in a patient stabilized on tacrolimus leads to decreased tacrolimus clearance and toxic serum levels. Tacrolimus toxicity classically presents with acute kidney injury (due to afferent arteriolar vasoconstriction) and neurotoxicity (tremor, headache). The most appropriate next step is to discontinue the offending CYP3A4 inhibitor (diltiazem) and substitute it with a rate-control agent that does not significantly interact with CYP3A4, such as the beta-blocker metoprolol. Tacrolimus should also be temporarily withheld until levels return to the therapeutic range.

Step-by-Step Solution

1
Identify the primary clinical problem and its etiology.
The patient presents with acute kidney injury, tremor, and headache in the setting of a markedly elevated serum tacrolimus level (24 ng/mL).
These findings are classic for acute calcineurin inhibitor toxicity, which requires immediate intervention to prevent permanent renal damage.
2
Analyze the patient's medication history to find the root cause of the toxicity.
The recent addition of diltiazem, a potent CYP3A4 inhibitor, decreased the metabolism of tacrolimus, leading to its rapid systemic accumulation.
Tacrolimus is heavily dependent on the hepatic and intestinal CYP3A4 enzyme system for clearance.
3
Determine the appropriate treatment modification.
The offending interacting agent (diltiazem) must be discontinued. For continued rate control of atrial fibrillation, a non-interacting alternative like metoprolol should be initiated.
Removing the CYP3A4 inhibitor allows tacrolimus metabolism to normalize, resolving the acute toxicity while maintaining necessary cardiac treatment.

Key Concept

The metabolism of calcineurin inhibitors (like tacrolimus) is strongly dependent on the CYP3A4 enzyme system; concurrent administration of CYP3A4 inhibitors (such as diltiazem) causes rapid drug accumulation leading to acute kidney injury and neurotoxicity.
Estimated Time:1m 30s
Question 4071Question →

A team of public health researchers is designing a cluster-randomized trial to evaluate the efficacy of a new peer-support intervention for improving glycemic control in adults with type 2 diabetes. The primary outcome is the absolute change in hemoglobin A1c over 12 months. Preliminary sample size calculations indicate that, based on the maximum number of clinics willing to participate, the study will only have 65% power to detect a 0.5% difference in hemoglobin A1c between the intervention and usual care groups at a standard two-tailed alpha of 0.05. The investigators must revise their protocol to achieve a minimum of 80% statistical power before institutional review board submission.

Which of the following protocol modifications would successfully increase the statistical power of this trial? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Restricting the inclusion criteria to a narrower baseline hemoglobin A1c range to create a more homogeneous study population; Extending the duration of the intervention to produce a larger expected mean difference in hemoglobin A1c between the two groups

Answer

The correct modifications are restricting the inclusion criteria to a narrower baseline hemoglobin A1c range, and extending the duration of the intervention to produce a larger expected mean difference.
The correct answers correctly identify that power can be augmented by decreasing sample variance (via a more homogeneous study population) and by increasing the magnitude of the intervention's true effect size.

Step-by-Step Solution

1
Identify the mathematical components of statistical power (1−β1 - \beta).
Power is positively influenced by a larger sample size (nn), a larger effect size (Δ\Delta), and a higher significance level (α\alpha), while being negatively influenced by larger variance (σ2\sigma^2).
Understanding the power formula is necessary to evaluate which protocol changes will increase the probability of detecting a true difference.
2
Evaluate the impact of altering sample variance.
Restricting inclusion criteria creates a more homogeneous population, which decreases the variance (σ2\sigma^2) and thereby increases power.
Lower variance means the signal-to-noise ratio improves, allowing the statistical test to more easily identify differences between groups.
3
Evaluate the impact of altering the effect size.
Modifying the intervention to yield a larger expected difference between groups increases the effect size (Δ\Delta), thereby increasing power.
A larger separation between the means of the two groups is easier to detect statistically than a smaller separation.
4
Reject the distracting modifications.
Dichotomizing continuous data discards information (decreasing power). Lowering α\alpha to 0.01 makes it harder to reject the null (decreasing power). Designing the trial to detect a smaller effect size with a fixed nn yields lower power.
These common misconceptions either reduce the information available for analysis or set a more stringent mathematical threshold, both of which reduce the likelihood of finding a true positive result.

Key Concept

Statistical power can be increased by increasing sample size, increasing the magnitude of the expected effect size, decreasing the variance of the sample, or increasing the acceptable Type I error rate (α\alpha).
Question 4072Question →

Match each clinical research scenario or statistical objective to the most appropriate measure of association or impact used to quantify it.

Click a left item, then click its matching right item

Items

Investigators recruit hospitalized patients with severe acute pancreatitis and compare their history of thiazide diuretic use to that of patients admitted for non-pancreatic conditions.
A cardiovascular trial utilizes a Kaplan-Meier estimator to report the relative likelihood of a myocardial infarction occurring at any precise moment among patients on a novel antiplatelet drug versus standard therapy.
Researchers studying a cohort of industrial miners calculate the specific fraction of chronic beryllium disease cases that would theoretically not have occurred if the miners had never been exposed to beryllium dust.
A clinical trial demonstrates that an experimental weight-loss medication increases the absolute risk of cholelithiasis by 4%4\%. Clinicians calculate how many patients must be prescribed the drug to expect one extra case of gallstones.

Matches

Show answer & explanation

Answer

The scenarios correctly match to: Case-control study with Odds Ratio (OR), Survival analysis with Hazard Ratio (HR), Proportion of disease due to exposure with Attributable Risk Percent (ARP), and Patient count for one adverse event with Number Needed to Harm (NNH).
Each statistical measure serves a highly specific epidemiological function. Case-control studies necessitate the use of an Odds Ratio because incidence cannot be directly measured. Survival analyses utilize Hazard Ratios to compare instantaneous event rates over a continuum of time. Attributable Risk Percent isolates the proportion of disease incidence directly resulting from a specific exposure. Finally, the Number Needed to Harm translates absolute risk increases into a clinically actionable patient count.

Step-by-Step Solution

1
Analyze the pancreatitis study design.
Identified as a case-control study (comparing diseased patients to non-diseased controls based on past exposure).
Case-control studies require the Odds Ratio because true disease incidence rates are unknown.
2
Evaluate the cardiovascular trial using Kaplan-Meier estimators.
Identified as a time-to-event survival analysis.
Hazard Ratios uniquely measure the instantaneous relative risk over time, accounting for censored patient data in survival analysis.
3
Determine the metric for the fraction of disease due to beryllium.
Identified as the proportion of incidence attributable to the exposure.
Attributable Risk Percent (ARP=RR−1RRARP = \frac{RR - 1}{RR}) calculates the exact percentage of disease cases in the exposed group that are directly caused by the exposure.
4
Calculate the metric associated with a 4%4\% absolute risk increase for gallstones.
Identified as the Number Needed to Harm.
The question asks for the number of patients treated to cause one adverse event, calculated as NNH=1Absolute Risk IncreaseNNH = \frac{1}{\text{Absolute Risk Increase}}.

Key Concept

Selection of epidemiological metrics based on specific study designs and clinical objectives.
Question 4073Question →

A hospital research ethics committee is reviewing several clinical trial protocols and post-study analyses. Match each specific trial scenario or parameter description to the statistical concept it best represents.

Click a left item, then click its matching right item

Items

A trial concludes that a novel biologic significantly reduces rheumatoid arthritis flares compared to placebo, but later definitive evidence shows the drug is completely ineffective.
A small pilot study concludes a novel surgical technique does not reduce postoperative infection rates, although the technique truly is superior to the standard approach.
Before initiating a study, investigators determine there is an 80% probability they will successfully detect a true 2-day reduction in intensive care unit length of stay.
Investigators design a trial based on their hypothesis that the new cardiovascular intervention will yield a 15% absolute reduction in 30-day mortality.

Matches

Show answer & explanation

Answer

The scenarios correctly match to: False positive finding = Type I error; False negative finding = Type II error; Probability of detecting a true difference = Statistical power; Anticipated magnitude of benefit = Expected effect size.
A Type I error occurs when researchers incorrectly reject a true null hypothesis (a false positive). A Type II error occurs when researchers fail to reject a false null hypothesis (a false negative). Statistical power (1−β1 - \beta) is the probability of correctly rejecting a false null hypothesis. The expected effect size is the clinically meaningful difference researchers anticipate observing between groups.

Step-by-Step Solution

1
Analyze the first scenario regarding the biologic agent.
The trial found a significant benefit, but reality shows no effect (false positive).
Identifying that the study claimed an effect that does not exist in reality points to a Type I error.
2
Analyze the second scenario regarding the surgical technique.
The trial found no benefit, but reality shows the technique is superior (false negative).
Identifying that the study missed a true effect characterizes a Type II error.
3
Evaluate the pre-study probability calculation.
The scenario describes an 80% probability of successfully detecting a true difference.
This probability represents the study's ability to avoid a Type II error, which is statistical power.
4
Examine the hypothesized 15% reduction in mortality.
This is the clinical difference the researchers anticipate observing.
This value represents the expected effect size required to calculate the necessary sample size.

Key Concept

Understanding the definitions and clinical manifestations of Type I errors (false positives), Type II errors (false negatives), statistical power, and effect size in clinical research.
Question 4074Question →

Establishing care for a new primary care physician, a 72-year-old biological male is evaluated in the ambulatory setting to discuss his health maintenance plan. He has a 45 pack-year history of cigarette smoking but successfully achieved cessation 12 years ago. His medical history includes severe chronic obstructive pulmonary disease requiring continuous home oxygen therapy, as well as New York Heart Association class III heart failure with a left ventricular ejection fraction of 25%. Current medications include sacubitril-valsartan, carvedilol, spironolactone, empagliflozin, and multiple inhaled therapies. His most recent colonoscopy at age 65 was unremarkable, and he received the 20-valent pneumococcal conjugate vaccine last year. When discussing preventive cancer screening, the patient inquires about his risk for lung cancer and whether he should undergo imaging. Based on current guidelines, which of the following is the most appropriate recommendation regarding lung cancer screening for this patient?

Show answer & explanation

Answer: Advise against screening, as his comorbid conditions substantially limit his candidacy for curative surgical intervention

Answer

The correct approach is to advise against lung cancer screening because the patient's severe comorbid conditions (oxygen-dependent COPD and advanced heart failure) substantially limit his life expectancy and candidacy for curative surgical intervention.
The correct answer advises against screening due to the patient's severe comorbidities. While the patient meets the standard numerical parameters for lung cancer screening (age 50-80, ≥\ge 20 pack-year smoking history, and quit within the past 15 years), current United States Preventive Services Task Force (USPSTF) guidelines explicitly state that screening should be discontinued if a patient develops a health problem that substantially limits their life expectancy or their ability to undergo curative lung surgery. This patient's continuous oxygen requirement for severe COPD combined with advanced heart failure with reduced ejection fraction makes the risks of curative surgical intervention (such as a lobectomy) prohibitively high. Therefore, screening would not offer a mortality benefit and could lead to cascading harms from invasive diagnostic procedures.

Step-by-Step Solution

1
Evaluate the patient's demographic and smoking data against standard screening criteria.
The patient is 72 years old, has a 45 pack-year smoking history, and quit 12 years ago, which superficially meets the standard criteria (age 50-80, ≥\ge 20 pack-years, currently smoke or quit within 15 years).
Establishing baseline numerical eligibility is the first step in assessing the need for lung cancer screening.
2
Assess the patient's clinical status and comorbidities.
The patient has severe, oxygen-dependent chronic obstructive pulmonary disease and NYHA class III heart failure with an ejection fraction of 25%.
Comorbidities heavily influence the risk-benefit ratio of cancer screening, particularly in older adults.
3
Apply United States Preventive Services Task Force (USPSTF) exclusion caveats for lung cancer screening.
USPSTF guidelines state screening should be discontinued if a patient develops a health problem that limits life expectancy or the ability to tolerate curative lung surgery (e.g., lobectomy).
Patients who cannot safely undergo resection will not experience a mortality benefit from screening and may be subjected to harmful invasive diagnostic procedures.

Key Concept

Lung cancer screening with low-dose computed tomography should not be performed in patients whose severe comorbidities substantially limit life expectancy or the ability to undergo curative thoracic surgery, even if they meet the age and smoking history criteria.
Question 4075Question →

A 72-year-old man with end-stage heart failure secondary to ischemic cardiomyopathy is admitted to the inpatient hospice unit. He has an implantable cardioverter-defibrillator (ICD) that also provides biventricular pacing. Over the past week, his condition has deteriorated significantly; he is now bedbound and requires continuous intravenous morphine for severe resting dyspnea. He remains fully alert, oriented, and capable of communicating his wishes. Today, he experienced three painful ICD shocks for episodes of ventricular tachycardia. He tells the attending physician, "These shocks are agonizing. Please turn this machine off so I can pass peacefully." The patient's wife expresses deep distress and states, "I want him to be comfortable, but isn't turning off his heart device the same as physician-assisted suicide? Can't we just give him medication for the rhythm instead?" Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Deactivate the defibrillation function of the ICD while maintaining the pacing function

Answer

Deactivate the defibrillation function of the ICD while maintaining the pacing function.
The patient has decision-making capacity and has requested the withdrawal of a life-sustaining treatment that is causing him pain. Ethically and legally, deactivating an ICD is considered withdrawal of medical therapy, not physician-assisted suicide or euthanasia. The most appropriate clinical approach is to deactivate the defibrillation (shock) function to eliminate the agonizing shocks, while leaving the biventricular pacing function active. The pacing function helps maintain cardiac output and synchrony, and turning it off could precipitate acute hemodynamic deterioration and worsen his dyspnea, which contradicts the primary goal of comfort care.

Step-by-Step Solution

1
Assess the patient's decision-making capacity.
The patient is fully alert, oriented, and clearly communicating his wishes, confirming he has the capacity to make medical decisions.
Capacity is the foundation for respecting patient autonomy in end-of-life care.
2
Evaluate the ethical implications of withdrawing the device.
Deactivating an ICD is legally and ethically considered the withdrawal of life-sustaining treatment, which is permissible and distinct from physician-assisted suicide.
Understanding the ethical distinction is necessary to counsel the distressed family and comply with the patient's request.
3
Determine the optimal technical management of the ICD.
The defibrillation (shock) function should be turned off to prevent pain, but the biventricular pacing function should be left on to maintain cardiac synchrony and prevent acute symptom worsening.
In palliative care, interventions that provide symptom relief (like pacing) are maintained, while those that cause distress (like shocks) are discontinued.

Key Concept

Management of Implantable Cardioverter-Defibrillators (ICDs) and ethical withdrawal of life-sustaining therapy at the end of life.
Question 4076Question →

An investigative team conducts a multicenter prospective trial assessing a newly developed targeted therapy, Navituzumab, for the prevention of relapses in patients with relapsing-remitting multiple sclerosis. A total of 2,500 patients are enrolled and equally divided into two groups: one receiving standard interferon-beta therapy and the other receiving Navituzumab.

The relapse data over a 3-year follow-up period are presented in the table below:

Treatment GroupTotal PatientsPatients with Relapse
Standard Therapy1,250250
Navituzumab1,250150

Based on these study findings, how many patients need to be treated with Navituzumab instead of standard therapy for 3 years to prevent one additional clinical relapse?

Show answer & explanation

Answer: 13

Answer

13
The correct answer is 13. The Number Needed to Treat (NNT) is calculated as the reciprocal of the Absolute Risk Reduction (ARR). The Control Event Rate (CER) is the incidence of relapse in the standard therapy group, which is 250/1250=0.20250 / 1250 = 0.20. The Intervention Event Rate (IER) is the incidence in the Navituzumab group, which is 150/1250=0.12150 / 1250 = 0.12. The ARR is the difference between these rates: 0.20−0.12=0.080.20 - 0.12 = 0.08. The NNT is 1/0.08=12.51 / 0.08 = 12.5. By epidemiological convention, NNT is always rounded up to the next whole number to ensure that at least one outcome is prevented. Therefore, 12.512.5 rounds up to 13.

Step-by-Step Solution

1
Calculate the incidence of relapse in both the control and intervention groups.
Control Event Rate (CER) = 250/1250=0.20250 / 1250 = 0.20 (20%20\%). Intervention Event Rate (IER) = 150/1250=0.12150 / 1250 = 0.12 (12%12\%).
These rates are required to determine the absolute risk difference between the two treatments.
2
Calculate the Absolute Risk Reduction (ARR).
ARR = CER−IER=0.20−0.12=0.08\text{CER} - \text{IER} = 0.20 - 0.12 = 0.08 (8%8\%).
ARR represents the absolute difference in risk of the outcome between the standard therapy and Navituzumab groups.
3
Calculate the raw Number Needed to Treat (NNT).
NNT = 1/ARR=1/0.08=12.51 / \text{ARR} = 1 / 0.08 = 12.5.
NNT indicates the number of patients that must be treated over a specific period to prevent one adverse outcome.
4
Apply epidemiological rounding rules to the NNT.
12.512.5 is rounded up to 1313.
NNT must always be rounded up to the next highest whole number. Treating 12 patients would theoretically prevent only 0.960.96 relapses, which is less than one complete event.

Key Concept

Number Needed to Treat (NNT) calculation and appropriate rounding rules.
Question 4077Question →

A 72-year-old man is evaluated in the emergency department for a 2-day history of productive cough, subjective fevers, and increasing fatigue. His medical history is significant for hypertension and benign prostatic hyperplasia. He lives alone in a second-story apartment with no elevator.

Vital signs are:
- Temperature: 38.1°C (100.6°F)
- Blood pressure: 128/78 mmHg
- Heart rate: 92/min
- Respiratory rate: 18/min
- Oxygen saturation: 95% on room air

Laboratory studies reveal:
- Leukocyte count: 11,500/mm³
- Blood urea nitrogen: 16 mg/dL
- Serum creatinine: 1.0 mg/dL

Chest radiography demonstrates a left lower lobe consolidation. The patient is alert and fully oriented. Based on objective scoring systems (e.g., CURB-65 score of 1, Pneumonia Severity Index Class II), his medical severity suggests he could be safely treated as an outpatient.

However, during the evaluation, the patient demonstrates profound generalized weakness. He requires the assistance of two staff members to transfer from the stretcher to a bedside chair and is unable to ambulate independently. When the physician discusses the care plan, the patient asks, "Can't I just go home with some pills?" but states he will follow the physician's medical advice.

Which of the following is the most appropriate next step in the disposition of this patient?

Show answer & explanation

Answer: Admit to a general medical floor for treatment and multidisciplinary functional evaluation

Answer

Admit to a general medical floor for treatment and multidisciplinary functional evaluation
The correct disposition is admission to a general medical floor for treatment and multidisciplinary functional evaluation. While the patient's objective medical severity scores (CURB-65 of 1, PSI Class II) suggest he is at low risk for mortality and could theoretically be treated with oral antibiotics as an outpatient, his acute functional decline makes home discharge unsafe. He requires a two-person assist for transfers and lives alone in a second-story apartment with no elevator. This profound inability to perform basic activities of daily living (ADLs) and lack of social support mandates an acute inpatient admission. During the admission, he will receive medical treatment for his pneumonia while undergoing a formal evaluation by physical therapy, occupational therapy, and social work to determine his long-term disposition needs, which may eventually include a transition to a skilled nursing facility (SNF).

Step-by-Step Solution

1
Calculate objective medical severity scores for community-acquired pneumonia.
The patient has a CURB-65 score of 1 and PSI Class II, which generally indicate a low risk of mortality.
Standard guidelines recommend evaluating mortality risk to guide initial triage decisions for pneumonia.
2
Assess the patient's functional status and social environment.
The patient requires a two-person assist for transfers, cannot ambulate, and lives alone in an inaccessible apartment.
Objective medical scores must be contextualized with the patient's ability to safely care for themselves at home.
3
Synthesize medical and functional data to determine the final disposition.
The severe functional deficit overrides the low medical severity score, mandating inpatient admission to a general medical floor.
An acute loss of independence in activities of daily living requires inpatient multidisciplinary evaluation (PT/OT, social work) alongside medical treatment.

Key Concept

In patients with acute illnesses like community-acquired pneumonia, profound functional impairment and lack of social support override low objective medical severity scores (e.g., CURB-65), necessitating inpatient admission for safety and multidisciplinary evaluation.
Question 4078Question →

An ambulatory care clinic evaluates a 54-year-old biological male for a routine health maintenance visit. His past medical history is notable for well-controlled type 2 diabetes mellitus and primary hypertension. The patient smoked one pack of cigarettes daily for 25 years but successfully quit 4 years ago. He does not consume alcohol or use recreational drugs. His immunizations are up to date, including a Tdap booster received 3 years ago and a complete two-dose series of the recombinant zoster vaccine administered at age 50. He has never received a pneumococcal vaccination. A review of his electronic medical record shows a screening colonoscopy performed at age 47 that revealed no polyps or abnormalities. He has no history of recent chest imaging or abdominal ultrasonography. He currently feels well and reports no new symptoms. Which of the following preventive interventions are indicated for this patient during today's visit? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Annual screening with low-dose computed tomography of the chest; Administration of the 20-valent pneumococcal conjugate vaccine

Answer

The indicated interventions are annual screening with low-dose computed tomography of the chest and administration of the 20-valent pneumococcal conjugate vaccine.
The correct answers are annual screening with low-dose computed tomography of the chest and administration of the 20-valent pneumococcal conjugate vaccine. According to current USPSTF guidelines, annual lung cancer screening with low-dose computed tomography is recommended for adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. This patient is 54 years old, has a 25 pack-year history, and quit 4 years ago, making him fully eligible. Furthermore, the Advisory Committee on Immunization Practices (ACIP) recommends pneumococcal vaccination (e.g., a single dose of the 20-valent pneumococcal conjugate vaccine) for adults aged 19 to 64 years with certain underlying medical conditions, including diabetes mellitus.

Step-by-Step Solution

1
Analyze the patient's demographics and social history.
54-year-old male with a 25 pack-year smoking history who quit 4 years ago.
Identifies eligibility for lung cancer screening and evaluates long-term vascular risks.
2
Assess the patient's medical history for vaccination indications.
The patient has type 2 diabetes mellitus and has no prior history of pneumococcal vaccination.
Determines criteria for adult immunizations in patients under 65 years of age based on comorbid conditions.
3
Evaluate the timeline of prior screening tests against standard intervals.
The patient had a normal colonoscopy 7 years ago at age 47.
Determines if repeat colorectal screening is due based on the standard 10-year interval for a normal exam.
4
Cross-reference all findings with current USPSTF and ACIP guidelines.
Lung cancer screening and pneumococcal vaccination are indicated; colonoscopy, abdominal aortic aneurysm screening, and osteoporosis screening are not indicated.
Ensures precise adherence to evidence-based preventive care recommendations for the patient's exact profile.

Key Concept

Application of age- and risk-based preventive screening guidelines, specifically lung cancer screening in former smokers and pneumococcal vaccination in adults with diabetes.
Question 4079Question →

During a departmental grand rounds, a pulmonologist presents a proposal for a new prospective clinical trial. The study aims to evaluate whether a novel inhaler formulation reduces the frequency of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) compared to standard therapy. Initial calculations indicate that 600600 subjects are required to achieve 80%80\% power at an α=0.05\alpha = 0.05. However, the trial's recruitment period is strictly limited, and realistic estimates suggest a maximum enrollment of only 400400 subjects. The principal investigator asks the research committee for strategies to maintain the study's 80%80\% statistical power despite the smaller-than-planned sample size.

Which of the following design modifications is most likely to accomplish this objective?

Show answer & explanation

Answer: Limiting participation to patients with a history of frequent exacerbations to increase the expected absolute effect size

Answer

Limiting participation to patients with a history of frequent exacerbations to increase the expected absolute effect size
Statistical power is the probability of correctly rejecting the null hypothesis when a true effect exists. It is directly related to the sample size and the effect size, and inversely related to the variance. Because the sample size in this scenario must be reduced from 600 to 400, the investigators must increase the expected absolute effect size to maintain the same 80%80\% statistical power. By restricting the study to patients with a history of frequent exacerbations (a high-risk group), the baseline rate of events increases. This typically leads to a larger absolute difference between the treatment and control groups, effectively increasing the effect size and preserving statistical power for a given sample size.

Step-by-Step Solution

1
Identify the relationship between sample size, effect size, and statistical power.
Statistical power depends on sample size, effect size, variance, and alpha level.
Understanding the determinants of power is necessary to evaluate the proposed study modifications.
2
Evaluate the impact of a reduced sample size.
A reduction in sample size from 600 to 400 subjects will decrease the statistical power if all other parameters remain constant.
Power is directly proportional to sample size.
3
Determine which parameter modification can offset the loss of power.
To maintain power with a smaller sample size, the study must either increase the effect size, increase the alpha level, or decrease the variance.
These parameters mathematically balance the sample size in power calculations.
4
Select the option that correctly applies one of these compensatory modifications.
Limiting participation to a high-risk group increases the baseline event rate, which increases the expected absolute effect size and preserves statistical power.
This is a standard clinical trial enrichment strategy when sample sizes are constrained by feasibility or budget.

Key Concept

Statistical power can be maintained despite a reduced sample size by increasing the expected effect size, such as by restricting enrollment to a higher-risk patient population with a higher baseline event rate.

Alternative Method

Power can also be conceptualized through the formula for continuous outcomes: n=2×((Z1−α/2+Z1−β)×σΔ)2n = 2 \times \left( \frac{(Z_{1-\alpha/2} + Z_{1-\beta}) \times \sigma}{\Delta} \right)^2. If nn decreases, you must either increase Δ\Delta (effect size), increase α\alpha (decrease Z1−α/2Z_{1-\alpha/2}), or decrease σ\sigma (variance) to maintain the equation's balance.
Estimated Time:1m 30s
Question 4080Question →

Match each clinical scenario to the most appropriate disposition or care setting.

Click a left item, then click its matching right item

Items

72-year-old man, 5 days post-ischemic stroke; medically stable with severe left-sided hemiparesis. He is highly motivated and able to actively participate in 3 hours of physical, occupational, and speech therapy daily.
85-year-old woman, 7 days post-hip fracture repair; medically stable but significantly deconditioned. She requires physical therapy but can only tolerate 45 to 60 minutes of activity per day due to fatigue.
65-year-old man evaluated in the emergency department for community-acquired pneumonia. He has acute confusion, BUN 35 mg/dL, respiratory rate 32/min, and blood pressure 85/50 mmHg.
58-year-old woman, 4 days into treatment for vertebral osteomyelitis. She is medically stable, fully ambulatory, independent in all activities of daily living, but requires 6 weeks of intravenous antibiotics.
78-year-old man, 10 days post-COPD exacerbation. He is medically stable but remains bedbound and requires total assistance for all activities of daily living. He has advanced dementia, no rehabilitation potential, and his family cannot provide care at home.

Matches

Show answer & explanation

Answer

The correct matches are based on strict clinical guidelines and Medicare criteria for facility transitions, prioritizing therapy tolerance, acuity scores (like CURB-65), and the distinction between skilled vs. custodial needs.
Matching each patient to the correct disposition setting requires applying specific criteria: IRFs strictly require 3 hours of daily therapy tolerance, SNFs are for skilled needs with lower therapy tolerance, ICUs are for critical illness (indicated by high prognostic scores like CURB-65), home infusion is optimal for stable patients needing only prolonged IV therapy, and custodial care is reserved for those lacking skilled needs but requiring ongoing ADL support.

Step-by-Step Solution

1
Analyze the post-stroke patient's functional status and rehabilitation capacity.
The patient is stable and can tolerate 3 hours of multidisciplinary therapy daily.
Tolerating 3 hours of intensive therapy daily is the defining requirement for Inpatient Rehabilitation Facility (IRF) placement.
2
Analyze the post-operative hip fracture patient's functional status.
The patient needs rehabilitation but can only tolerate 45-60 minutes daily.
Patients requiring active rehabilitation who cannot tolerate the 3-hour IRF requirement are appropriately triaged to a Skilled Nursing Facility (SNF).
3
Calculate the CURB-65 score for the patient presenting with pneumonia.
The score is 5 (Confusion, BUN >19, RR ≥30, BP <90/60, Age ≥65).
A CURB-65 score of 3 or higher, particularly with hemodynamic compromise, indicates severe pneumonia necessitating intensive care.
4
Evaluate the osteomyelitis patient's medical needs versus functional independence.
The patient is independent in all activities of daily living but requires prolonged IV antibiotics.
Stable, independent patients requiring prolonged IV therapy can safely receive Home Infusion Services (OPAT), avoiding institutionalization.
5
Determine the bedbound patient's eligibility for skilled care versus custodial care.
The patient has no rehabilitation potential but requires total care for activities of daily living.
Without a need for skilled nursing or active physical therapy, a patient does not qualify for an SNF and requires Custodial Care (Long-Term Care).

Key Concept

Appropriate care setting disposition depends on synthesizing medical acuity (e.g., CURB-65 score), functional status, rehabilitation potential, daily therapy tolerance (3-hour rule for IRF), and the need for skilled vs. custodial care.
PreviousPage 204 / 237Next